[HTML][HTML] Análise crítica do uso dos anti-TNF na era dos novos agentes biológicos na doença inflamatória intestinal
CCG Lima, NSF Queiroz, CW Sobrado… - Arq …, 2020 - pesquisa.bvsalud.org
BACKGROUND: Inflammatory bowel diseases (IBD), both Crohn's disease and ulcerative
colitis, are chronic immune-mediated diseases that present a relapsing and remitting course …
colitis, are chronic immune-mediated diseases that present a relapsing and remitting course …
Therapeutic drug monitoring guided anti-tumour necrosis factor therapy in inflammatory bowel disease (IBD): Gastroenterological Society of Australia (GESA) …
N Mitrev - 2017 - ses.library.usyd.edu.au
INTRODUCTION: Growing evidence supports the use of therapeutic drug monitoring (TDM)
to guide anti-tumour necrosis factor (TNF) drug treatment among patients with inflammatory …
to guide anti-tumour necrosis factor (TNF) drug treatment among patients with inflammatory …
In the presence of loss of response, what is the advantage of TDM to the patient? In the presence of loss of response, what is the advantage of TDM to the patient?
AH Steinhart - mentoringinibd.com
Several recent publications have confirmed that knowing tumour necrosis factor-α (TNF-α)
antagonist trough levels will result in different decisions that using clinical information alone …
antagonist trough levels will result in different decisions that using clinical information alone …
In the presence of loss of response, what is the advantage of TDM to the healthcare provider? In the presence of loss of response, what is the advantage of TDM to the …
NV Casteele - mentoringinibd.com
Loss of response to biologic therapy is a common problem that appears to be multifactorial
and related to development of antidrug antibodies (ADAs), alterations in drug clearance …
and related to development of antidrug antibodies (ADAs), alterations in drug clearance …
[HTML][HTML] In the presence of loss of response, what should I do if my patient has a high infliximab level? In the presence of loss of response, what should I do if my …
SPL Travis - Relation - mentoringinibd.com
Evidence concerning the appropriate clinical strategy in patients with adequate drug levels
and loss of response is somewhat limited, as prospective randomized trials are lacking in …
and loss of response is somewhat limited, as prospective randomized trials are lacking in …
[PDF][PDF] Monitorování farmakokinetiky infliximabu u idiopatických střevních zánětů
P Svoboda, T Kupka - casopisvnitrnilekarstvi.cz
Therapeutic drug monitoring is a strategy utilized to optimize biological therapy. It consists in
the drug level measurement before the next dose is due, when the drug concentration …
the drug level measurement before the next dose is due, when the drug concentration …
Avaluació de la utilitat del monitoratge farmacocinètic dels fàrmacs anti-TNF en pacients amb malaltia inflamatòria intestinal en dos hospitals amb diferent grau d' …
M Vila Currius - 2020 - dugi-doc.udg.edu
El factor de necrosi tumoral (TNF) actua com un potent inductor de la inflamació en la
malaltia de Crohn (MC) i colitis ulcerosa (CU). Pel tractament d'aquestes malalties …
malaltia de Crohn (MC) i colitis ulcerosa (CU). Pel tractament d'aquestes malalties …
[PDF][PDF] Is Therapeutic Drug Monitoring for Anti-tumour Necrosis Factor Agents in Adults With Inflammatory Bowel Disease Ready for Standard of Care? A Systematic …
AM Goldowsky, Y Chen… - Journal of Crohn's and …, 2020 - researchgate.net
Introduction: Using therapeutic drug monitoring [TDM] in adult patients with inflammatory
bowel disease [IBD] remains controversial. We conducted a systematic review and meta …
bowel disease [IBD] remains controversial. We conducted a systematic review and meta …
Clinical value of CT-P13 trough levels, an infliximab biosimilar, in the management of inflammatory bowel disease
AE González, PS Segura, DO Lara, SL García… - … Clínica (English Edition), 2020 - Elsevier
Introduction CT-P13 is a biosimilar drug of infliximab (IFX), effective in patients with
inflammatory bowel disease (IBD). The monitoring of levels of IFX and anti-IFX antibodies is …
inflammatory bowel disease (IBD). The monitoring of levels of IFX and anti-IFX antibodies is …
Comparison of two kits of anti-infliximab antibodies plasmatic measurement
R Charfi, I Mahmoud, FB Salem, M Moalla… - Annales de Biologie …, 2019 - jle.com
Infliximab (IFX) is a chimeric monoclonal antibody which has proven its efficacy in the
treatment of inflammatory diseases. However, its efficacy can be limited by the development …
treatment of inflammatory diseases. However, its efficacy can be limited by the development …